Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes.
R
R
Boizel
G
G
Bruttmann
P Y
PY
Benhamou
S
S
Halimi
F
F
Stanke-Labesque
D000328:Adult; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000201:enzymology* / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000201:enzymology* / Q000652:urine; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D017999:Leukotriene E4 / Q000652:urine; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology*; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine
D007004:Hypoglycemic Agents; D007328:Insulin; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D017999:Leukotriene E4; D001094:Arachidonate 5-Lipoxygenase